Valneva Cuts Full-Year Guidance, Announces 10-15% Workforce Reduction After Wider Q1 Loss
VALN sits 24% above its 52-week low of $5.06.
Summary
Valneva reported a significantly wider net loss of EUR32.1 million for Q1 2026, compared to EUR9.2 million in Q1 2025, primarily due to one-off effects and lower sales. More critically, the company downgraded its full-year product sales guidance to EUR135-EUR150 million from EUR145-EUR160 million, citing an emerging adverse trend in travel vaccine uptake. To address these challenges, Valneva announced a restructuring plan that includes a 10-15% global workforce reduction and an expected 25-35% cut in 2026 operating expenses. While the company's cash position was strengthened by the recently completed €84 million offering (as seen in the April 30th timeline entries), the guidance cut and layoffs signal significant operational adjustments and headwinds. Traders will closely monitor the effectiveness of these cost-saving measures and future vaccine demand.
At the time of this announcement, VALN was trading at $6.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $611.8M. The 52-week trading range was $5.06 to $12.25. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.